Lisa Campbell
Director of Regulatory Strategy

Lisa Campbell leads the regulatory and medical writing functions at Richmond Pharmacology. She is responsible for guiding regulatory strategy across all clinical studies, overseeing submissions, and supporting regulatory engagements with UK, EU, and international authorities.

She brings over two decades of experience in drug development, clinical medicine, and regulatory science. Lisa previously held senior consultancy positions at NDA Regulatory Science and SSI Strategy, where she advised on global clinical programmes for gene therapies and rare diseases.

During her nine years at the MHRA, Lisa was a Senior Medical Assessor in the Clinical Trials Unit. Her work included developing innovative licensing processes (ILAP), shaping patient and public involvement strategies, and leading assessments for first-in-human and adaptive platform trials.

Lisa trained in Obstetrics and Gynaecology and holds an MD (postgraduate research degree) in Diabetes in Pregnancy. She is widely published in Nature Medicine, BMJ Open, and JAMA, and is an expert in regulatory compliance, trial design, and policy development.

At Richmond Pharmacology, Lisa is focused on delivering innovative, inclusive, and compliant regulatory solutions that accelerate access to new therapies.

Back to experts

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event